1. Development of a nanoplatform for mRNA delivery to activated hepatic stellate cells (aHSCs) in liver fibrosis.
2. Tweaking the composition and properties of lipid nanoparticles (LNPs) enables ligand-free targeting.
3. LNPs demonstrate a pKa-dependent intrahepatic selectivity and hydrophobic scaffolds control their tropism to organs.
The article “Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis” is an informative and well-written piece that provides an overview of the development of a platform for selective delivery of mRNA to aHSCs, which are fundamental players in the progression of liver fibrosis. The article is reliable and trustworthy as it provides detailed information on the composition and properties of lipid nanoparticles (LNPs), their mRNA delivery efficiency, selectivity, potency, robustness, and biosafety, as well as some mechanistic aspects of their selective delivery to aHSCs. Furthermore, the article discusses potential clinical applications for this novel platform.
The article does not appear to be biased or one-sided as it presents both sides equally by providing evidence for its claims and exploring counterarguments where necessary. It also does not contain any promotional content or partiality towards any particular viewpoint or opinion. Additionally, possible risks associated with this platform are noted throughout the article, such as potential toxicity issues due to high doses of mRNA administration.
In conclusion, this article is reliable and trustworthy due to its comprehensive coverage of the topic at hand and lack of bias or promotional content.